-
Bioetech Insider Buying: ArQule Inc. (NASDAQ:ARQL), Akebia Therapeutics (NASDAQ:AKBA), Oragenics Inc. (NYSEMKT:OGEN), MediciNova Inc. (NASDAQ:MNOV), Cyclacel Pharmaceuticals (NASDAQ:CYCC)
ArQule Inc. (NASDAQ:ARQL) Director Susan L. Kelley acquired 50,000 shares of ArQule stock on the open market in a transaction that occurred on Thursday, November 13th. The stock was purchased at an average price of $1.20 per share, for a total transaction of $60,000.00. Following the completion of the acquisition, the director now directly owns…
-
Trending Stocks: American Airlines Group Inc. (NASDAQ:AAL), First Solar (NASDAQ:FSLR), Enterprise Financial Services Corp. (NASDAQ:EFSC), MediciNova (NASDAQ:MNOV), Five Oaks Investment (NYSE:OAKS)
On 23 October American Airlines Group Inc. (NASDAQ:AAL) said on Thursday that third-quarter net income soared 87 percent. The airline earned $1.66 per share, excluding special items, beating analysts’ estimates of $1.63, according to Thomson Reuters I/B/E/S. American Airlines Group Inc. (NASDAQ:AAL) in last trading activity advanced 0.14% to close at $43.20. Company weekly performance…
-
Investors Watch List: Veracyte (NASDAQ:VCYT), MediciNova Inc. (NASDAQ:MNOV), Sealed Air Corporation (NYSE:SEE), NewBridge Bancorp (NASDAQ:NBBC), The Fresh Market (NASDAQ:TFM)
Equities researchers at Stephens started coverage on shares of Veracyte, Inc. (NASDAQ:VCYT) in a research report issued on Tuesday. The firm set an “overweight” rating and a $14.00 price target on the stock. Stephens’ price target points to a potential upside of 52.84% from the company’s current price. Veracyte, Inc. (NASDAQ:VCYT) in last trading activity…
-
Top Wall Street Stories: Bristol-Myers Squibb Company (NYSE:BMY), JD.com(NASDAQ:JD), MediciNova Inc. (NASDAQ:MNOV), Johnson & Johnson (NYSE:JNJ), Independent Bank Corporation (NASDAQ:IBCP)
Bristol-Myers Squibb Company (NYSE:BMY) on Friday reported third-quarter profit of $721 million. The New York-based company said it had profit of 43 cents per share. Earnings, adjusted for non-recurring costs, came to 45 cents per share. The results beat Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was for earnings…
-
Microcap Losers: Alpha Pro Tech (NYSEMKT:APT), Neuralstem(NYSEMKT:CUR), Hudson Technologies Inc. (NASDAQ:HDSN), Protalix BioTherapeutics(NYSEMKT:PLX), MediciNova Inc. (NASDAQ:MNOV)
Alpha Pro Tech Ltd (NYSEMKT:APT) VP Charles D. Montgomery unloaded 43,570 shares of the company’s stock in a transaction that occurred on Tuesday, September 23rd. The shares were sold at an average price of $2.90, for a total transaction of $126,353.00. Following the completion of the sale, the vice president now directly owns 145,920 shares…
-
Biotech gainers: Anacor Pharmaceuticals Inc (NASDAQ:ANAC), RXi Pharmaceuticals Corp (NASDAQ:RXII), Trevena Inc (NASDAQ:TRVN), MediciNova, Inc. (NASDAQ:MNOV)
Anacor Pharmaceuticals (NASDAQ:ANAC) had its price objective hosited by Jefferies Group from $24.00 to $25.00 in a report released on Friday. Jefferies Group currently has a buy rating on the stock. Shares of Anacor Pharmaceuticals Inc (NASDAQ:ANAC) closed at $19.50 in last trading session. Yesterday share price of the company was traded in the range…
-
Biotech Active Movers – VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), MediciNova, Inc. (NASDAQ:MNOV)
Vivus Inc. (NASDAQ:VVUS) will test its weight loss drug Qsymia in a pilot program with Aetna Inc. Hartford-based Aetna (NYSE:AET) will incorporate Qsymia into a program that combines it with “lifestyle support for weight loss.” Shares of VIVUS, Inc. (NASDAQ:VVUS) closed at $9.46 in last trading session. Yesterday share price of the company was traded…
-
Worst Biotech Stocks To Watch – AFFY, CYTX, OPXA, MNOV
Affymax, Inc. (NASDAQ:AFFY) is expected to released its fourth quarter earning 2012 on Thursday this week. The company in less than two weeks mortified shareholders after it and along with its licensing partner Takeda Pharmaceuticals declared the voluntary recall of anemia drug Omontys. This would be conference call for Omontys is far more important to…